The HeartMate III: Design and In Vivo Studies of a Maglev Centrifugal Left Ventricular Assist Device

• Published in: Artificial organs 2001-05, Vol.25 (5), p.386-391
• Main Authors: Loree II, Howard M., Bourque, Kevin, Gernes, David B., Richardson, J. Scott, Poirier, Victor L., Barletta, Natale, Fleischli, Andreas, Foiera, Giampiero, Gempp, Thomas M., Schoeb, Reto, Litwak, Kenneth N., Akimoto, Takehide, Kameneva, Marina, Watach, Mary J., Litwak, Philip
• Format: Article
• Language: English
• Subjects: Animals; Cattle; Centrifugal pump; Centrifugation; Heart-Assist Devices - adverse effects; Hemorheology; In vivo studies; Left ventricular assist device; Magnetic suspension; Magnetics; Prosthesis Design; Rotary blood pump; Titanium
• ISSN: 0160-564X; 1525-1594
• DOI: 10.1046/j.1525-1594.2001.025005386.x

: A compact implantable centrifugal left ventricular assist device (LVAD) (HeartMate III) featuring a magnetically levitated impeller is under development. The goal of our ongoing work is to demonstrate feasibility, low hemolysis, and low thrombogenicity of the titanium pump in chronic bovine in vivo studies. The LVAD is based on so‐called bearingless motor technology and combines pump rotor, drive, and magnetic bearing functions in a single unit. The impeller is rotated (θz) and levitated with both active (X, Y) and passive (Z, θx, θy) suspension. Six prototype systems have been built featuring an implantable titanium pump (69 mm diameter, 30 mm height) with textured blood contacting surfaces and extracorporeal electronics. The pumps were implanted in 9 calves (≤100 kg at implant) that were anticoagulated with Coumadin (2.5 ≤ INR ≤ 4.0) throughout the studies. Six studies were electively terminated (at 27–61 days), 1 study was terminated after the development of severe pneumonia and lung atelectasis (at 27 days) another study was terminated after cardiac arrest (at 2 days) while a final study is ongoing (at ≈100 days). Mean pump flows ranged from 2 to 7 L/min, except for brief periods of exercise at 6 to 9 L/min. Plasma free hemoglobin ranged from 4 to 10 mg/dl. All measured biochemical indicators of end organ function remained within normal range. The pumps have met performance requirements in all 9 implants with acceptable hemolysis and no mechanical failures.